Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells

2 Mar 2021

Abstract excerpt

Non-viral platforms can be applied rapidly and cost-effectively for chimeric antigen receptor (CAR)-T cell manufacturing. In the present paper, we describe in detail a clinically relevant manufacturing process for NKG2D CAR-T cells through electroporation of CAR-encoding piggyBac transposon plasmids and in vitro expansion with K562 artificial antigen-presenting cells. With an optimized protocol, we generated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33816644
DOI: 10.1016/j.omtm.2021.02.023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cellsPMID 33816644Read ↗

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.Semantic proximity Read ↗

Autologous antigen-presenting cells efficiently expand piggyBac transposon CAR-T cells with predominant memory phenotypeSemantic proximity Read ↗

Engineering strategies to safely drive CAR T-cells into the futureSemantic proximity Read ↗

Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection.Semantic proximity Read ↗

Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene deliverySemantic proximity Read ↗

Automated, scaled, transposon-based production of CAR T cellsSemantic proximity Read ↗

Recent Progress in NKG2D CAR-NK Cells for Cancer ImmunotherapySemantic proximity Read ↗

Current Non-Viral-Based Strategies to Manufacture CAR-T CellsSemantic proximity Read ↗

Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.Semantic proximity Read ↗

Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and AccessibilitySemantic proximity Read ↗

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapySemantic proximity Read ↗

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.